Suzetrigine for moderate to severe acute pain
- 24 March 2025
- journal article
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 46 (5) , 480-481
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- National Institute of Neurological Disorders and Stroke (R01NS100947)
- National Institute of Neurological Disorders and Stroke (R21NS136070)
- National Institute of Neurological Disorders and Stroke (R33NS124923)
- National Institute of Neurological Disorders and Stroke (R61NS130199)
This publication has 10 references indexed in Scilit:
- Pharmacology and Mechanism of Action of Suzetrigine, a Potent and Selective NaV1.8 Pain Signal Inhibitor for the Treatment of Moderate to Severe PainPain and Therapy, 2025
- NaV1.8 inhibitor poised to provide opioid-free pain reliefNature Reviews Drug Discovery, 2024
- Selective Inhibition of Na V 1.8 with VX-548 for Acute PainNew England Journal of Medicine, 2023
- The Role of Voltage-Gated Sodium Channels in Pain SignalingPhysiological Reviews, 2019
- Advances in Achieving Opioid Analgesia Without Side EffectsFrontiers in Pharmacology, 2018
- Management of Postoperative Pain: A Clinical Practice Guideline From the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative CouncilThe Journal of Pain, 2016
- Causes and Consequences of Inadequate Management of Acute PainPain Medicine, 2010
- The Development of New Analgesics Over the Past 50 Years: A Lack of Real Breakthrough DrugsAnesthesia & Analgesia, 2010
- A-803467, a potent and selective Na v 1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the ratProceedings of the National Academy of Sciences, 2007
- Contribution of Nav1.8 Sodium Channels to Action Potential Electrogenesis in DRG NeuronsJournal of Neurophysiology, 2001